Initial Targets. The Exclusive Research Option Right is deemed exercised by MAGENTA for the Initial Targets as of the Effective Date. In connection with MAGENTA’s exercise of its Exclusive Research Option Right for the Initial Targets, MAGENTA will pay HDPR the Research Target Fees as more fully set forth in Section 9.1.2.
Appears in 2 contracts
Sources: Exclusive Research, Development Option and License Agreement (Magenta Therapeutics, Inc.), Exclusive Research, Development Option and License Agreement (Magenta Therapeutics, Inc.)